Tinib 0.89mg (Tivozanib Hydrochloride) is a potent VEGF receptor tyrosine kinase inhibitor manufactured by Pharma Lord, specifically designed to treat advanced renal cell carcinoma (RCC). Tivozanib Hydrochloride blocks the action of vascular endothelial growth factor (VEGF), a protein that stimulates the formation of blood vessels (angiogenesis) essential for tumor growth. By inhibiting VEGF receptors, Tivozanib cuts off the tumor's blood supply, slowing or stopping its growth.
Advantages of Tivozanib Hydrochloride:
- Targeted Anti-Cancer Therapy: It specifically targets VEGF receptors, reducing tumor angiogenesis and growth, making it highly effective for kidney cancer.
- Improved Progression-Free Survival: Clinical studies show Tivozanib extends progression-free survival in patients with advanced RCC compared to other treatments.
- Fewer Side Effects: Tivozanib is generally well-tolerated with fewer side effects compared to other VEGF inhibitors, improving patients' quality of life.
- Once-Daily Oral Administration: Its oral form provides ease of use and convenience for patients, reducing the need for frequent hospital visits.
- Ideal for Long-Term Use: Its favorable safety profile makes it suitable for long-term therapy in treating renal cell carcinoma.
Uses of Tinib 0.89mg:
- Renal Cell Carcinoma (RCC): Tivozanib Hydrochloride is used for the treatment of advanced renal cell carcinoma, especially in patients who have not responded to other therapies.
- Monotherapy or Combination Therapy: It can be used as a stand-alone treatment or in combination with other cancer therapies to enhance treatment outcomes.